维普期刊资源整合服务平台（V6.5）

44篇 您的检索式：作者名="STEWART CF"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): a 12- year experience in more than 900 patients显示文摘	Blitzer A Brin MF Stewart CF	1998	Laryngoscope1998，108，：	1
2	UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics,but not severe toxicity in patients receiving low-dose irinotecan显示文摘	Stewart CF Panetta JC O’Shaughnessy MA	2007	J Clin Oncol2007，25，18：	1
3	Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia) : a 12-year experience in more than 900 patients显示文摘	Blitzer A Brin MF Stewart CF	1998	Laryngoscope1998，108，：	1
4	Phase I clinical trial of cilengitide in children with refractory brain tumors:Pediatric Brain Tumor Consortium Study PBTC-012显示文摘	MacDonald TJ Stewart CF Kocak M		0，，：	1
5	Phase I tri- M oforal irinotecan and temozolomide for children with re- lapsed hish-risk neuroblastoma:a new approach to neu- roblastoma therapy consortium study 显示文摘	Wagner LM Villablanca JG Stewart CF	2009	J Clin Oncol2009，27，8：	1
6	Phase I trial of MK-0752 inchildren with refractory CNS malignancies:a pediatric brain tumorconsortium study显示文摘	Fouladi M Stewart CF Olson J	2011	J Clin Oncol2011，29，26：	1
7	Phase I trial of MRK-560 in children with refractory cNS malignancies: a pediatric brain tumor consortium study 显示文摘	FouLadi M Stewart CF Olson J	2011	J Cli Oncol2011，29，26：	1
8	Phase I clinical trial of Cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012 显示文摘	Mac-Donald TJ Stewart CF Kocak M	2008	J Clin Oncol2008，26，6：	1
9	Relation between Irofulven (MG1-114) systemic exposure and tumor response in human solid tumor xenografts 显示文摘	Leggas M Stewart CF Woo MH	2002	Clin Cancer Res2002，8，9：	1
10	UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan显示文摘	Stewart CF Panetta JC O'Shaughnessy MA	2007	J Clin Oncol2007，25，18：	1
11	UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics,but not severe toxicity in patients receiving low-dose irinotecan显示文摘	Stewart CF Panetta JC O'Shaughnessy MA	2007	J Clin Oncol2007，25，18：	1
12	Phase I trial of MK-0752in children with refractory CNS malignancies : a pediatric braintumor consortium study 显示文摘	Fouladi M Stewart CF Olson J	2011	J Clin Oncol2011，29，26：	1
13	Phase I dosage-finding and pharmacokinetic (PK) study of intravenous topotecan and oral erlotinib in patients (pts) with refractory solid tumors显示文摘	Stewart CF Tagen M Schwartzberg LS	2014	Cancer Chemother Pharmacol2014，73，3：	1
14	Combination ofcladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia显示文摘	Inaba H Stewart CF Crews KR	2010	Cancer2010，116，1：	1
15	Botulinum toxin management of spasmodic dysphonia( laryngeal dystonia): a 12-year expe rienee in more than 900 patients 显示文摘	Blitzer A Brin MF Stewart CF	1998	Laryngoscope1998，108，：	1
16	In vitro and in vivo activity of topotecan against human B-linegae acute lymphoblastlc leukemia cells 显示文摘	Uckun FM Stewart CF Reaman G	1995	Blood1995，85，4：	1
17	Excitotoxicity of and 6-OH-DOPA:implications for Parkinson's and Huntington's diseases显示文摘	Olney JW Zorumski CF Stewart GR	1990	Exp Neurol1990，108，：	1
18	Pilot induction regimen incorporating pharmacokinetically guided topoteean for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oneology Group study显示文摘	Park JR Scott JR Stewart CF	2011	J Clin Oneol2011，29，33：	1
19	Topoisomerase Ⅰ interactive agents 显示文摘	Kirstein MN Turner PK Stewart CF	2002	Cancer Chemother Biol Response Modif2002，20，：	1
20	A molecular bi-ology and phase Ⅱ trial of lapatinih in children with re-fractory CNS malignancies:a pediatric brain tumor con-sortium study显示文摘	Fouladi M Stewart CF Blaney SM	2013	J Neurooncol2013，114，2：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示